MedPath

Interest of Positive Expiratory Pressure (PEP) Delivery by EzPAP® After Cardiac Surgery in the Management of Postoperative Atelectasis

Not Applicable
Completed
Conditions
Pulmonary Atelectasis
Interventions
Other: KP group
Other: KM group
Registration Number
NCT02262182
Lead Sponsor
Nantes University Hospital
Brief Summary

Pulmonary atelectasis is a frequent respiratory postoperative complication in cardiac surgery. Classically, the treatment of these patients is based on manual chest physiotherapy. Our objective is to evaluate the interest of association of positive end expiratory delivery sessions with the EzPAP® device. We perform a prospective monocentric, open label trial. Patients with atelectasis after scheduled cardiac surgery with cardiopulmonary bypass are included. They benefit from manual chest therapy and are randomised to receive or not positive end expiratory pressure sessions twice a day. The primary endpoint is the effect of this treatment on atelectasis radiological score after 2 days of treatment. The secondary endpoints are: oxygen saturation(SpO2)/inspired oxygen(FiO2) ratio, qualitative evaluation of ventilatory function, respiratory \& cardiac rate, pain, inspiratory pressure (sniff test), patient satisfaction, duration of intensive care unit (ICU) and hospital stay.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
80
Inclusion Criteria
  • Patients admitted in ICU after cardiac surgery by sternotomy with cardiopulmonary bypass presenting a pulmonary atelectasis after extubation, diagnosed by chest X-ray in postoperative period (day1 to day 2).
  • Patients over 18 years of age
  • Informed patient
Exclusion Criteria
  • Cardiac arrhythmia
  • Hemodynamic instability (mean blood pressure < 65 mmHg or > 95 mmHg)
  • Respiratory rate > 35/min
  • Undrained pneumothorax
  • Predictable trachea intubation or emergent surgery
  • Patient oral refusal

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
KP groupKP groupPEP delivery by EzPAP® device with manual chest physiotherapy .
KM groupKM groupManual chest physiotherapy only;
Primary Outcome Measures
NameTimeMethod
Radiological atelectasis scoreDay 2 post-inclusion

This score was first described by Pasquina P et al in 2004

Secondary Outcome Measures
NameTimeMethod
SpO2/FiO2 ratioDays 1, 2 and 3 post inclusion

This ratio is measured before and after session

Radiological atelectasis scoreDays 1 and 3 post-inclusion

This score was first described by Pasquina P et al in 2004

Qualitative evaluation of ventilatory function (nasal flaring, superficial tachypnea, use of accessory muscle, paradoxical abdominal respiration, cough difficulty) before and after sessionDays 1, 2 and 3 post inclusion

This respiratory function assessment is performed in a qualitative way

Dyspnea evaluationDays 1, 2 and 3 post inclusion

Dyspnea is measured with a visual analogue scale before and after session

Inspiratory pressure measurementDays 2 and 3 post inclusion

This measurement (so called sniff test) is assessed with MicroRPM device before and after session

Pain evaluationDays 1, 2 and 3 post inclusion

Pain is measured with a visual analogue scale before and after session

Vesicular murmur intensityDays 1, 2 and 3 post inclusion

Vesicular murmur absent = 0, reduce = 1, present and normal = 2 Intensity is measured with an electronic stethoscope before and after session

Assessment of patient satisfaction and tolerance of EzPAP deviceDay 3 post inclusion

A questionnaire of 10 answer with semi-quantitative scale

Cardiac and respiratory rateDays 1, 2 and 3 post inclusion

Measurement performed at the same time as SPO2 (patients are monitored)

Trial Locations

Locations (1)

Nantes Universitary Hospital

🇫🇷

St-Herblain, France

© Copyright 2025. All Rights Reserved by MedPath